Blis Technologies reports 10% revenue growth

Blis Technologies has reported revenue and earnings growth for the year ended March 31, 2025.

Revenue for the financial year was $12.6 million, a 10% increase from the previous year.

This growth was driven by solid sales of finished products and modest growth in business-to-business revenue.

However, higher royalty revenue was partially offset by softness in ingredient revenue from European customers.

The company's ebitda reached $1m, a 26% improvement, while net profit was $800,000, up from $600,000 in the prior year.

The ebitda result exceeded guidance due to reduced expenditure attributed to the prolonged review by China regulators.

Blis Technologies acknowledged spending considerable time dealing with unexpected patent issues during the year.

The company is currently in negotiations with its largest customer in Europe and a party associated with that customer to reach an acceptable outcome.

It remains focused on delivering revenue growth and improved profitability by working with partners in key business-to-business markets, primarily in the US.

The company entered the new financial year with cautious optimism, citing growing demand for science-backed probiotics.